Those PD-1 inhibitors have demonstrated inspiring efficacy in advanced NSCLC as monotherapy or in combination with standard platinum doublet chemotherapy (Yy et al., 2020; Zhou et al., 2020; Zhou et al., 2021a; Zhou et al., 2021b; Lu et al., 2021; Wang et al., 2021). Here, PDCD1 is linked to non-small cell lung carcinoma.